New Hope is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Millennium Biotechnologies, Inc. Announces the Launch of a Revolutionary, New Product, Defenzyme, on the Heals of Promising New Research Being Published on Its Active Ingredient, GliSODin

BASKING RIDGE, N.J., Nov 18, 2003 (BUSINESS WIRE) -- Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTCBB: MBTG) is pleased to announce the development and launch of a new nutraceutical product called DefenZyme(TM) which includes their exclusive ingredient GliSODin(R), which is the first orally effective, vegetarian form the body's most important antioxidant defense superoxide dismutase (SOD). Since SOD plays such a critical role in every single cell of the body, GliSODin(R) represents one of the most dynamic, clinically relevant and versatile nutraceuticals to come to market.

Equally significant, is the announcement by Isocell, SA, owner and patent holders of GliSODin(R), that there are over 20 research articles on GliSODin(R) that have been submitted for publication to some of the most prestigious medical journals. "The research is very significant and Defenzyme(TM) represents a true breakthrough in nutraceutical science" states Millennium's VP of Research & Product Development Carl Germano, RD, CNS, CDN. "The human studies demonstrate the ability of GliSODin(R) to reduce oxidative stress and protect the body from free radicals, lower lactic acid and upregulate the body's antioxidant defenses - SOD, Glutathione and Catalase. In addition to the human studies, promising animal data points to the importance of GliSODin's(R) effects on inflammatory messengers, positive influence on the immune system and as a useful nutritional adjunct to medical care."

In addition to Millennium's flagship products RESURGEX(R) and RESURGEX Plus(TM), the launch of Defenzyme(R)(TM) represents another milestone for Millennium in its quest to supply quality, effective medical nutritional support products to improve the quality of life for many. Millennium Biotechnologies, Inc. has several joint venture opportunities, to sell, market and distribute Defenzyme(TM). Negotiations with these joint venture partners are currently in progress with the primary focus on maximizing market penetration.

Interestingly, Resurgex(R) and Resurgex Plus(TM), contain this critically important, orally effective form of SOD (GliSODin(R)) along with several other significant nutritional components. This important information is highlighted in a new book Balance Your Brain Balance Your Body by noted neurologist Dr. Jay Lombard, a John Wiley & Sons publication. Both Resurgex(R) and Resurgex Plus(TM) are being reimbursed by Medicaid in certain states, and Millennium plans to launch them in other targeted locales upon further approvals for reimbursement.

Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies, Group, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized enteral nutritional formulas and nutraceuticals. The company's first two products, Resurgex(R) and Resurgex Plus(TM), are the first multiple action nutritional formulas designed to assist in increasing energy, maintaining lean muscle, reducing oxidative stress and supporting immune function. For more information about Millennium Biotechnologies, Inc., log onto

This news release contains forward-looking statements that are based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions on the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex(R), Resurgex Plus(TM) and Defenzyme(TM) and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.